Chief Technology Officer
BSc PhD
Dr. Schaffer has over 20 years of experience in driving innovation in life sciences technology and large-scale isotope production. Prior to Telix, Dr. Schaffer was CTO at ARTMS Inc. (ARTMS) (acquired by Telix in 2024), as well as Director, Life Science at TRIUMF, Canada’s particle accelerator research centre, since 2012. He is widely recognized for his role in the buildout and transformation of the TRIUMF Life Sciences program, which included design and construction of a major multi-cyclotron radiochemistry facility and the development of the ARTMS QUANTM® Irradiation System (QIS®) for large-scale isotope production, which was commercialized and later acquired by Telix.